Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Rafael Moliner, Mykhailo Girych, Vera Kovaleva, Caroline Biojone, Giray Enkavi, Lina Antenucci, Katja Kaurinkoski, Mirjami Kuutti, Sven Sakson, Cecilia Cannarozzo, Nina Seiffert, Anna Rubiolo, Hele Haapaniemi, Elsa Meshi, Elina Nagaeva, Tiina Öhman, Tomasz Róg, Esko Kankuri, Marçal Vilar, Markku Varjosalo, Perttu Permi, Ilpo Vattulainen, Cecilia A. Brunello, Erik F. Kot, Sergey A. Goncharuk, Senem Merve Fred, Lauri Elsilä, Cassiano R.a.f. Diniz, Esa R. Korpi, Константин С. Минеев, Märt Saarma, Plínio Casarotto, Eero Castrén
Nature Neuroscience June 1, 2023 DOI: 10.1038/s41593-023-01316-5 via OpenAlex
Summary
AI-generated from the abstractPsychedelics such as LSD and psilocin produce fast and lasting antidepressant effects by directly binding to the TrkB receptor, the receptor for brain-derived neurotrophic factor (BDNF). These compounds bind to TrkB with affinities 1,000 times higher than other antidepressants like fluoxetine and ketamine, and they interact with a distinct but partially overlapping site within the transmembrane domain of TrkB dimers. In mice, the neuroplasticity and antidepressant-like effects of psychedelics depend on TrkB binding and endogenous BDNF signaling, not on serotonin 2A receptor activation. However, LSD-induced head twitching requires serotonin 2A activation and is independent of TrkB binding. This suggests that high-affinity TrkB positive allosteric modulators without serotonin 2A activity could retain antidepressant benefits without hallucinogenic effects.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Mice |
| Interventions | LSD psilocin fluoxetine ketamine |
| Topics | Neuroplasticity |
| Keywords | Neuroscience Psychology Brain-derived neurotrophic factor Receptor |
| Citations | 439 |
| Key finding | Psychedelics directly bind to TrkB with high affinity to produce antidepressant-like effects independently of serotonin 2A receptor activation. |
Abstract
Abstract Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to TrkB with affinities 1,000-fold higher than those for other antidepressants, and that psychedelics and antidepressants bind to distinct but partially overlapping sites within the transmembrane domain of TrkB dimers. The effects of psychedelics on neurotrophic signaling, plasticity and antidepressant-like behavior in mice depend on TrkB binding and promotion of endogenous BDNF signaling but are independent of serotonin 2A receptor (5-HT 2A ) activation, whereas LSD-induced head twitching is dependent on 5-HT 2A and independent of TrkB binding. Our data confirm TrkB as a common primary target for antidepressants and suggest that high-affinity TrkB positive allosteric modulators lacking 5-HT 2A activity may retain the antidepressant potential of psychedelics without hallucinogenic effects.